A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
about
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in TumorPhase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Development of the rat model of lapatinib-induced diarrhoea.Characteristics of triple-negative breast cancerResiliency and vulnerability in the HER2-HER3 tumorigenic driver.Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.Two dimensions in targeting HER2.Lapatinib for advanced or metastatic breast cancerDifferential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsNovel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrheaPharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveLapatinib and breast cancer: current indications and outlook for the future.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Management of recurrent head and neck cancer: recent progress and future directions.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Management of pulmonary toxicity associated with targeted anticancer therapies.Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.Activity-based kinase profiling of approved tyrosine kinase inhibitors.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.Chemotherapy and QT Prolongation: Overview With Clinical Perspective.Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.Physicochemical Characterization and Cyclodextrin Complexation of the Anticancer Drug Lapatinib
P2860
Q27342948-62B518F2-127B-4CB3-85AF-47817E599BABQ33597447-3C01BA78-9E15-4845-8534-297008DDCAB4Q33999288-56B615B6-BC2F-4D60-8B5B-D57900DA7C6FQ34479003-7B3F670C-F489-4DB3-9542-9913702A98FFQ34551761-16104219-8B48-4DAF-A69F-06ED18812AD7Q34886764-784253BD-50A3-4B4F-81B7-ACF4816D62FEQ35743883-80CC2DAA-73F0-4F7A-BDB6-BF603D482EC1Q35879834-17EAFE77-C5C0-4797-B716-945CDB30213EQ35895143-F7BE3840-9206-416D-ADDA-A6482B04ECB1Q35913209-50CF472F-8806-4C12-A517-AD851773EAE0Q35967385-6AFE742B-B9AF-4406-A091-E720948246DBQ36262855-DA9175B4-6E79-411D-A7D2-5115B7FDB567Q36384340-36573483-C0FE-41FA-B20B-0CB701B023B7Q36600202-096B8E32-B5FE-4811-9226-322DF02D4D0AQ37376191-F34DA7A0-7A70-4768-9869-FB276B5498F2Q37498669-AA6BD9A4-8D30-421D-BC18-7F51D5E52DA8Q37580148-E95EF97C-A3E0-4E54-AECA-C61ADFB7462BQ37782086-A58FDE3F-8C9C-4187-AF8B-103A07B86D07Q37873453-3040410A-52A6-4DE9-9D6D-EDFCA53576DFQ37921278-2B71AA7F-B12F-4024-9C4C-5988F323D3C0Q38190857-A9EE1A9E-4A3D-428A-B6EF-941F0B787C15Q38570532-B1EB2856-DD34-48AD-9B43-D694AC7EAD7FQ39528587-7742C8D9-5BF1-4C1C-A672-501CB5E6E914Q39557421-EC048BE0-880F-4899-8D8F-4CFCA50D8EDEQ42713576-8526A1EB-5B54-4D01-B5A1-3362447229E2Q44312601-8AC42722-1AD7-47AB-94BA-84067E0C8696Q47569610-6DDDC6E8-5D52-4EF8-BA0B-3165A5D7788FQ47969048-7FB2F996-F85C-42E3-B716-4E2DD38378A0Q48363253-6F9608A8-0319-4C5F-81BC-935142D33D9CQ48461764-61B85178-4463-4CDC-A5F1-88660439B5E6Q48872511-67BBCB0E-1CD0-4157-AE26-FB475694AF4DQ54389879-E5D5C5F4-72EF-4F33-B3F3-D7FA59129D22Q54998494-803902A0-243E-40AC-BCE4-88C6F55AA096Q55274551-537BD097-2B9B-4F2C-9B7E-725C0ADB9923Q59145850-D5F291A4-DAB7-4C77-831E-BFA187A0F651
P2860
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A phase I and pharmacokinetic ...... ients with solid malignancies.
@ast
A phase I and pharmacokinetic ...... ients with solid malignancies.
@en
type
label
A phase I and pharmacokinetic ...... ients with solid malignancies.
@ast
A phase I and pharmacokinetic ...... ients with solid malignancies.
@en
prefLabel
A phase I and pharmacokinetic ...... ients with solid malignancies.
@ast
A phase I and pharmacokinetic ...... ients with solid malignancies.
@en
P2093
P2860
P1476
A phase I and pharmacokinetic ...... ients with solid malignancies.
@en
P2093
Charles W Taylor
Deborah A Smith
Howard A Burris
Kevin M Koch
Lini Pandite
Melissa J Versola
Neil Spector
Ronald A Fleming
Suzanne F Jones
P2860
P304
P356
10.1158/1078-0432.CCR-09-0369
P407
P577
2009-10-13T00:00:00Z